Home / Going-concern warnings / Replimune Group, Inc.
Filed 2026-06-29 路 Form 10-K 路 Accession 0001628280-26-045886 small
Price before filing: $11.63 (2026-06-26 close, split/dividend-adjusted)
Market cap at flag: $1.04B (2026-06-29) 路 Latest: $1.05B (2026-10-16)
| Window | REPL | SPY | vs SPY | |
|---|---|---|---|---|
| 30 days | -53.5% | +0.1% | -53.5% | 2026-07-29 |
| 90 days | +8.0% | +5.3% | +2.7% | 2026-09-28 |
| 180 days | pending | pending | until 2026-12-26 |
Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.
90 days before the flag: 6 insiders sold $637K (8 sales)
30 days after: none reported.
| Date | Insider | Type | Shares | Price | Value | 10b5-1 plan | Source |
|---|---|---|---|---|---|---|---|
| 2026-04-02 | Sarchi Christopher Chief Commercial Officer | Sale | 6,500 | $8.01 | $52K | yes | Form 4 |
| 2026-05-18 | Astley-Sparke Philip Director | Sale | 17,657 | $5.08 | $90K | no | Form 4 |
| 2026-05-18 | Hill Emily Luisa Chief Financial Officer | Sale | 7,812 | $5.08 | $40K | no | Form 4 |
| 2026-05-18 | Patel Sushil Chief Executive Officer, Director | Sale | 37,324 | $5.08 | $190K | no | Form 4 |
| 2026-05-18 | Sarchi Christopher Chief Commercial Officer | Sale | 8,626 | $5.08 | $44K | no | Form 4 |
| 2026-05-18 | Schwendenman Andrew Chief Accounting Officer | Sale | 7,894 | $5.08 | $40K | no | Form 4 |
| 2026-05-18 | Xynos Konstantinos Chief Medical Officer | Sale | 14,023 | $5.08 | $71K | no | Form 4 |
| 2026-06-01 | Sarchi Christopher Chief Commercial Officer | Sale | 12,000 | $9.24 | $111K | yes | Form 4 |
| 2026-06-29: red flag filed | |||||||
Open-market purchases and sales (Form 4 codes P and S) by officers, directors and 10% owners, by transaction date, from 2026-03-31 to 2026-07-29. Excludes option exercises, grants, gifts and tax withholding. Amended filings replace the originals; joint filings count once. Foreign private issuers do not file Form 4. Many insider sales are pre-scheduled (10b5-1 plans) and are not by themselves a sign of wrongdoing.
"As discussed in Note 1 to the consolidated financial statements, the Company has incurred recurring losses since its inception which raises substantial doubt about its ability to continue as a going concern."
Quoted from the filing. Source
The filing states that substantial doubt exists about the company's ability to continue as a going concern: it may not have enough cash to last the next 12 months. Expect dilution, debt deals or worse. An auditor's going-concern paragraph is the strongest form of this warning.
Going-concern opinion issued by: PricewaterhouseCoopers LLP
Source: independent auditor report in Form 10-K (period 2026-03-31)
Why this score: in auditor's report
Read the original filing on SEC.gov →
Not investment advice. Automated summary; verify against the filing.
The week's most serious auditor changes, restatements, late filings and going-concern warnings, in plain English. Free. Unsubscribe anytime.
Subscribe to the newsletter →
The signup form didn't load here (often an ad or privacy blocker). This opens beehiiv's secure signup page.
Form not showing? Subscribe on beehiiv →
Newsletter delivered by beehiiv. See our privacy policy.